Bayer’s Nubeqa drug won priority review status from the U.S. Food and Drug Administration, as the German drugmaker seeks to widen the use of the prostate cancer drug from an early disease stage to metastatic cases.
https://www.pharmalive.com/wp-content/uploads/2021/12/Blood-thinner-drug-Xarelto-tied-to-higher-rate-of-major-side-effects-study-Reuters-12-21-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-05-03 11:31:162022-05-03 12:30:58Bayer wins U.S. priority review of drug against metastatic prostate cancer